Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.390 -0.100 (-6.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Healthcare Stock to Keep an Eye On and 2 to Be Wary Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
3 Unprofitable Stocks Walking a Fine Line
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock
Via Benzinga
3 Stocks Under $10 with Open Questions
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
Earnings Scheduled For May 8, 2025
Via Benzinga
PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed
Via Stocktwits
Where Pacific Biosciences Stands With Analysts
Via Benzinga
The RealReal, Carnival, PacBio, Quest Resource, and Hudson Technologies Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. 
Via StockStory
Topics Artificial Intelligence Economy Stocks
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds
Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15... 
Via StockStory
Topics World Trade
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks,... 
Via StockStory
Topics Artificial Intelligence
3 Out-of-Favor Stocks Skating on Thin Ice
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
Topics Supply Chain
Where Pacific Biosciences Stands With Analysts
Via Benzinga
1 Russell 2000 Stock with Exciting Potential and 2 to Approach with Caution
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.3% year on year to $37.15 million. Its... 
Via StockStory
PacBio (PACB) Q1 Earnings: What To Expect
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
Via Benzinga
1 Volatile Stock to Target This Week and 2 to Keep Off Your Radar
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the... 
Via StockStory
Topics Artificial Intelligence
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most... 
Via StockStory
Topics Artificial Intelligence Government World Trade
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs
PacBio reaffirms 2025 revenue outlook and unveils cost-cutting measures as Vega system demand grows and Revio usage meets expectations. 
Via Benzinga
Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. 
Via StockStory
Topics Artificial Intelligence
Assessing Pacific Biosciences: Insights From 6 Financial Analysts
Via Benzinga
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV. 
Via Benzinga
3 Reasons to Sell PACB and 1 Stock to Buy Instead
Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 35.2% and now trades at $1.25. This was partly due to its softer quarterly results and might... 
Via StockStory
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. 
Via StockStory
Topics Artificial Intelligence
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
Via Benzinga
PacBio (NASDAQ:PACB) Misses Q4 Sales Targets
Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.